The primary efficacy end point was trough SDBP response at 26 weeks ; secondary efficacy end points included changes from baseline at trough in both standing and supine DBP and systolic blood pressure ( SBP ) , and heart rate after 4 , 8 , 16 , and 26 weeks ; SBP control ( reduction from baseline of > or = 10 mm Hg ) ; normalization of supine SDBP to < or = 90 mm Hg ; and the need for add-on HCTZ .
